WTX-712 / Werewolf Therap - LARVOL DELTA

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook (GlobeNewswire) - "Preclinical Portfolio: includes development candidates WTX-712 and WTX-518, our IL-21 and binding protein resistant IL-18 INDUKINE molecules, respectively, for treatment of cancer...In 2025, Werewolf plans to complete ongoing pre-clinical work to support IND-stage programs and seek strategic partnerships to advance these programs."

Preclinical • Oncology • Solid Tumor

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting (GlobeNewswire) - "Werewolf Therapeutics...announced that two posters will be presented at the upcoming Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas."

P1 data • Preclinical • Solid Tumor

WTX-712, a conditionally active IL-21 INDUKINETM molecule, induces a strong anti-tumor phenotype through a differentiated mechanism (AACR 2024) - "Anti-tumor efficacy was linked to expansion and activation of tumor infiltrating CD8 T cells with increased polyfunctionality. We will show additional mechanistic data evaluating the effect of WTX-712 dosing on immune populations, including tumor spatial profiling using different models."

Oncology • CD8 • GZMB • IL21

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting (GlobeNewswire) - "The WTX-712 data are summarized in a poster titled, 'WTX-712, a conditionally active IL-21 INDUKINE molecule, induces a strong anti-tumor phenotype through a differentiated mechanism' (Abstract #4078). Key takeaways reveal that: WTX-712 demonstrates inducibility and antitumor activity with regressions in the MC38 mouse tumor model; IL-21 HLE (half-life extended) has superior anti-tumor efficacy compared to IL-2 HLE therapy in mouse tumor models that are highly resistant to anti-PD-1/PD-L1 treatment, in part due to the activation of type-I IFN pathways; and IL-21 HLE promotes sustained expansion and activation of tumor infiltrating CD8 T cells with increased polyfunctionality and induces expression of cytotoxic effector molecules (Granzyme A, Granzyme B, and perforin)."

Preclinical • Oncology

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) - "In the first half of this year, we plan to present additional clinical data from our Phase 1/1b clinical trial of WTX-124, including updated monotherapy data and initial combination data, which we anticipate will build on the promising signals of antitumor activity and improved therapeutic index that we observed in the data presented at SITC last year. In addition, we plan to share data further demonstrating the performance of our platform in our preclinical programs at AACR. We also plan to share initial clinical data from WTX-330, our second clinical candidate, in the second quarter of 2024."

P1 data • Preclinical • Non-Hodgkin’s Lymphoma • Solid Tumor

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024 (GlobeNewswire) - "Werewolf Therapeutics...announced the publication of abstracts for upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California."

Preclinical • Oncology

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook (GlobeNewswire) - "In 2024, Werewolf plans to: Present preclinical data from WTX-712 in the first half of 2024; Present preclinical data from WTX-518 in the first half of 2024."

Preclinical • Oncology

Development of WTX-712, a conditionally active IL-21 INDUKINETM molecule for the treatment of cancer (SITC 2023) - "Utilizing multiplex immunofluorescence, we observed altered tumor architecture and activated immune infiltrates in tumors of WTX-712 treated mice compared to vehicle. Conclusions Together, these data support continued exploration of WTX-712, an IL-21 INDUKINETM molecule, as a therapy for cancer."

Oncology • CD8 • IL21

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting (GlobeNewswire) - "Human IL-21 receptor knock-in (hIL-21R KI) mice bearing syngeneic tumors were treated with WTX-712, an IL-21 INDUKINE molecule, or half-life extended human IL-21....WTX-712 exhibited activity with an expanded therapeutic window compared to half-life extended IL-21 in mouse syngeneic tumor models including complete regressions and protection against tumor growth upon rechallenge."

Preclinical • Oncology

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting (GlobeNewswire) - "Six abstracts, spanning Werewolf’s PREDATOR™ platform and INDUKINE™ pipeline, accepted for poster presentations at SITC annual meeting; Company to present interim first-in-human clinical data from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of WTX-124."

P1 data • Preclinical • Oncology • Solid Tumor

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire) - "Werewolf has nominated wholly owned candidate WTX-712 for preclinical development. WTX-712 is a conditionally activated IL-21 INDUKINE molecule in development for treatment of cancer. IL-21 is believed to promote expansion of immune cells in the tumor microenvironment resulting in antitumor immunity. A poster...will be presented on Monday, April 17, 2023, at 9:00 AM - 12:30 PM at the AACR Annual Meeting 2023 in Poster Section 24 under abstract number 1829."

New molecule • Preclinical • Oncology